双侧乳腺癌发生机制研究进展
Research Progress on the Mechanisms of Bilateral Breast Cancer
DOI: 10.12677/jcpm.2026.54261, PDF,    科研立项经费支持
作者: 秦 俭：济宁医学院临床医学院(附属医院)，山东 济宁；吕月涛*：济宁市第一人民医院乳腺外科，山东 济宁
关键词: 双侧乳腺癌；发生机制；生物学异质性；遗传易感性；免疫微环境；Bilateral Breast Cancer； Mechanisms； Biological Heterogeneity； Genetic Susceptibility； Immune Microenvironment
摘要: 双侧乳腺癌是乳腺癌中较少见但具有特殊生物学意义的类型，包括同步性双侧乳腺癌和异时性双侧乳腺癌。其发生并非单侧乳腺癌在双侧乳腺中的简单重复，而可能与独立第二原发、遗传易感性、共同内分泌和环境暴露、分子异质性及免疫微环境等因素相关。现有分子研究提示，多数双侧病灶更倾向于独立原发，少数病例可能具有共同克隆来源。本文围绕双侧乳腺癌的流行病学特征、肿瘤起源、发生机制、临床转化意义及新技术应用前景进行综述，以期为风险评估和个体化管理提供参考。
Abstract: Bilateral breast cancer is a relatively rare type of breast cancer with distinct biological significance, including synchronous bilateral breast cancer and metachronous bilateral breast cancer. Its occurrence is not a simple repetition of unilateral breast cancer in both breasts, but may be related to independent second primary tumors, genetic susceptibility, shared endocrine and environmental exposures, molecular heterogeneity, and the immune microenvironment. Current molecular studies suggest that most bilateral lesions are more likely to be independent primary tumors, whereas a small proportion of cases may have a common clonal origin. This review summarizes the epidemiological characteristics, tumor origin, mechanisms, and clinical translational significance of bilateral breast cancer, aiming to provide a reference for risk assessment and individualized management.
文章引用：秦俭, 吕月涛. 双侧乳腺癌发生机制研究进展[J]. 临床个性化医学, 2026, 5(4): 368-377. https://doi.org/10.12677/jcpm.2026.54261

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
[2] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263.
https://doi.org/10.3322/caac.21834
[3] Jiang, H., Zhang, R., Liu, X., Ran, R., Zhang, J., Liu, Y., et al. (2021) Bilateral Breast Cancer in China: A 10-Year Single-Center Retrospective Study (2006-2016). Cancer Medicine, 10, 6089-6098.
https://doi.org/10.1002/cam4.4141
[4] Hartman, M., Czene, K., Reilly, M., Adolfsson, J., Bergh, J., Adami, H., et al. (2007) Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast Cancer. Journal of Clinical Oncology, 25, 4210-4216.
https://doi.org/10.1200/jco.2006.10.5056
[5] Hamy, A.S., Abécassis, J., Driouch, K., et al. (2023) Evolution of Synchronous Female Bilateral Breast Cancers and Response to Treatment. Nature Medicine, 29, 646-655.
https://doi.org/10.1038/s41591-023-02216-8
[6] Li, B., Xu, W., Cao, J., Guo, D., Tao, Z., Jin, J., et al. (2023) A Study of Clinical and Molecular Characteristics in Bilateral Primary Breast Cancer. Cancer Medicine, 12, 15881-15892.
https://doi.org/10.1002/cam4.6226
[7] Schulze, A.K., Hoskin, T.L., Moldoveanu, D., Sturz, J.L. and Boughey, J.C. (2024) Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer. Annals of Surgical Oncology, 31, 947-956.
https://doi.org/10.1245/s10434-023-14451-x
[8] Jia, H., Zheng, Y., Wang, P., Wei, Z., Li, X., Fu, G., et al. (2022) A Retrospective Study on the Clinicopathologic Characteristics and Outcomes of 179 Cases of Synchronous and Metachronous Bilateral Breast Cancer in China. Clinical Breast Cancer, 22, e341-e349.
https://doi.org/10.1016/j.clbc.2021.09.009
[9] Hong, C., Zheng, Y., Geng, R., Hu, H., Zhong, Y., Guan, Q., et al. (2022) Clinicopathological Features and Prognosis of Bilateral Breast Cancer: A Single-Center Cohort Study Based on Chinese Data. Annals of Translational Medicine, 10, Article 742.
https://doi.org/10.21037/atm-21-5400
[10] Robbins, G.F. and Berg, J.W. (1964) Bilateral Primary Breast Cancers: A Prospective Clinicopathological Study. Cancer, 17, 1501-1527.
https://doi.org/10.1002/1097-0142(196412)17:12<1501::aid-cncr2820171202>3.0.co;2-p
[11] Chaudary, M.A., Millis, R.R., Hoskins, E.O.L., Halder, M., Bulbrook, R.D., Cuzick, J., et al. (1984) Bilateral Primary Breast Cancer: A Prospective Study of Disease Incidence. Journal of British Surgery, 71, 711-714.
https://doi.org/10.1002/bjs.1800710924
[12] Klevebring, D., Lindberg, J., Rockberg, J., Hilliges, C., Hall, P., Sandberg, M., et al. (2015) Exome Sequencing of Contralateral Breast Cancer Identifies Metastatic Disease. Breast Cancer Research and Treatment, 151, 319-324.
https://doi.org/10.1007/s10549-015-3403-6
[13] Begg, C.B., Ostrovnaya, I., Geyer, F.C., Papanastasiou, A.D., Ng, C.K.Y., Sakr, R.A., et al. (2018) Contralateral Breast Cancers: Independent Cancers or Metastases? International Journal of Cancer, 142, 347-356.
https://doi.org/10.1002/ijc.31051
[14] Alkner, S., Tang, M.E., Brueffer, C., Dahlgren, M., Chen, Y., Olsson, E., et al. (2015) Contralateral Breast Cancer Can Represent a Metastatic Spread of the First Primary Tumor: Determination of Clonal Relationship between Contralateral Breast Cancers Using Next-Generation Whole Genome Sequencing. Breast Cancer Research, 17, Article No. 102.
https://doi.org/10.1186/s13058-015-0608-x
[15] Song, F., Li, X., Song, F., Zhao, Y., Li, H., Zheng, H., et al. (2015) Comparative Genomic Analysis Reveals Bilateral Breast Cancers Are Genetically Independent. Oncotarget, 6, 31820-31829.
https://doi.org/10.18632/oncotarget.5569
[16] Yadav, S., Boddicker, N.J., Na, J., Polley, E.C., Hu, C., Hart, S.N., et al. (2023) Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Journal of Clinical Oncology, 41, 1703-1713.
https://doi.org/10.1200/jco.22.01239
[17] Lakeman, I.M.M., van den Broek, A.J., Vos, J.A.M., Barnes, D.R., Adlard, J., Andrulis, I.L., et al. (2021) The Predictive Ability of the 313 Variant-Based Polygenic Risk Score for Contralateral Breast Cancer Risk Prediction in Women of European Ancestry with a Heterozygous BRCA1 or BRCA2 Pathogenic Variant. Genetics in Medicine, 23, 1726-1737.
https://doi.org/10.1038/s41436-021-01198-7
[18] Hendricks, L.A.J., Hoogerbrugge, N., Mensenkamp, A.R., Brunet, J., Lleuger-Pujol, R., Høberg-Vetti, H., et al. (2023) Cancer Risks by Sex and Variant Type in PTEN Hamartoma Tumor Syndrome. JNCI: Journal of the National Cancer Institute, 115, 93-103.
https://doi.org/10.1093/jnci/djac188
[19] Scabia, V., Ayyanan, A., De Martino, F., Agnoletto, A., Battista, L., Laszlo, C., et al. (2022) Estrogen Receptor Positive Breast Cancers Have Patient Specific Hormone Sensitivities and Rely on Progesterone Receptor. Nature Communications, 13, Article No. 3127.
https://doi.org/10.1038/s41467-022-30898-0
[20] Mao, X., Omeogu, C., Karanth, S., Joshi, A., Meernik, C., Wilson, L., et al. (2023) Association of Reproductive Risk Factors and Breast Cancer Molecular Subtypes: A Systematic Review and Meta-Analysis. BMC Cancer, 23, Article No. 644.
https://doi.org/10.1186/s12885-023-11049-0
[21] Ding, S., Sun, X., Lu, S., Wang, Z., Chen, X. and Shen, K. (2021) Association of Molecular Subtype Concordance and Survival Outcome in Synchronous and Metachronous Bilateral Breast Cancer. The Breast, 57, 71-79.
https://doi.org/10.1016/j.breast.2021.03.005
[22] Wang, J., Chen, H., Koenig, J., Wu, Y., Bedrosian, I., Arun, B., et al. (2024) Discordance of Oncotype DX Scores in Synchronous Bilateral and Unilateral Multifocal Breast Cancers. Breast Cancer Research and Treatment, 203, 73-83.
https://doi.org/10.1007/s10549-023-07119-3
[23] El Bairi, K., Haynes, H.R., Blackley, E., et al. (2021) The Tale of TILs in Breast Cancer: A Report from the International Immuno-Oncology Biomarker Working Group. npj Breast Cancer, 7, Article No. 150.
[24] Harris, M.A., Savas, P., Virassamy, B., O’Malley, M.M.R., Kay, J., Mueller, S.N., et al. (2024) Towards Targeting the Breast Cancer Immune Microenvironment. Nature Reviews Cancer, 24, 554-577.
https://doi.org/10.1038/s41568-024-00714-6
[25] Loibl, S., André, F., Bachelot, T., Barrios, C.H., Bergh, J., Burstein, H.J., et al. (2024) Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 35, 159-182.
https://doi.org/10.1016/j.annonc.2023.11.016
[26] Metcalfe, K., Huzarski, T., Gronwald, J., Kotsopoulos, J., Kim, R., Moller, P., et al. (2024) Risk-Reducing Mastectomy and Breast Cancer Mortality in Women with a BRCA1 or BRCA2 Pathogenic Variant: An International Analysis. British Journal of Cancer, 130, 269-274.
https://doi.org/10.1038/s41416-023-02503-8
[27] Panet, F., Papakonstantinou, A., Borrell, M., Vivancos, J., Vivancos, A. and Oliveira, M. (2024) Use of ctDNA in Early Breast Cancer: Analytical Validity and Clinical Potential. npj Breast Cancer, 10, Article No. 50.
https://doi.org/10.1038/s41523-024-00653-3
[28] Nader-Marta, G., Monteforte, M., Agostinetto, E., Cinquini, M., Martins-Branco, D., Langouo, M., et al. (2024) Circulating Tumor DNA for Predicting Recurrence in Patients with Operable Breast Cancer: A Systematic Review and Meta-Analysis. ESMO Open, 9, Article 102390.
https://doi.org/10.1016/j.esmoop.2024.102390
[29] Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., et al. (2024) Spatial Transcriptomics Reveals Substantial Heterogeneity in Triple-Negative Breast Cancer with Potential Clinical Implications. Nature Communications, 15, Article No. 10232.
https://doi.org/10.1038/s41467-024-54145-w
[30] Mardamshina, M., Karagach, S., Mohan, V., Arad, G., Necula, D., Golani, O., et al. (2025) Integrated Spatial Proteomic Analysis of Breast Cancer Heterogeneity Unravels Cancer Cell Phenotypic Plasticity. Nature Communications, 16, Article No. 10482.
https://doi.org/10.1038/s41467-025-65477-6
[31] McGenity, C., Clarke, E.L., Jennings, C., Matthews, G., Cartlidge, C., Freduah-Agyemang, H., et al. (2024) Artificial Intelligence in Digital Pathology: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. npj Digital Medicine, 7, Article No. 114.
https://doi.org/10.1038/s41746-024-01106-8